trial · primary record
Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months
Advanced Small Intestine Cancer
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 22 |
| Primary completion | 2029-12-31 |
| Primary endpoint | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 in patients receiving Nalirifox per Napoli-3 regimen as first-line chemotherapy for advanced non-resectable small intestine and appendiceal cancers |
| Registry ID | NCT07060014 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:35.978Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07060014
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.